| 2015 |
NRSN2 promotes non-small cell lung cancer cell growth through the PI3K/Akt/mTOR signaling pathway, as demonstrated by loss- and gain-of-function experiments in NSCLC cell lines showing effects on cell growth but not invasion. |
Loss- and gain-of-function assays in NSCLC cell lines, western blot for pathway components |
International journal of clinical and experimental pathology |
Medium |
26045763
|
| 2015 |
NRSN2 inhibits hepatocellular carcinoma cell proliferation and promotes senescence and apoptosis by regulating PI3K/AKT signaling and the p53/p21 pathway, as shown by loss- and gain-of-function assays. |
CCK-8 assays, SA-β-gal staining, Annexin V/PI staining, western blot for PI3K/AKT and p53/p21 pathway components; loss- and gain-of-function in HCC cell lines |
Digestive diseases and sciences |
Medium |
26055238
|
| 2016 |
NRSN2 promotes malignant phenotype in ovarian cancer cells including anchorage-independent growth, invasion, and chemoresistance, and positively correlates with CD133 stem cell marker expression; Wnt canonical signaling and Twist/Akt/Erk axis are regulated by NRSN2. |
Loss- and gain-of-function assays, colony formation, subcutaneous tumor formation, invasion assays, western blot for Wnt/Akt/Erk pathway components |
Biomedicine & pharmacotherapy |
Medium |
27908706
|
| 2017 |
NRSN2 promotes osteosarcoma cell proliferation and growth through dysregulation of both PI3K/AKT/mTOR and Wnt/β-catenin signaling pathways, demonstrated by loss- and gain-of-function assays in vitro and in vivo. |
Loss- and gain-of-function assays in osteosarcoma cell lines, in vivo tumor growth assays, western blot for PI3K/AKT/mTOR and Wnt/β-catenin pathway components |
American journal of cancer research |
Medium |
28401012
|
| 2019 |
NRSN2 promotes breast cancer cell proliferation, migration, and invasion by activating PI3K/AKT/mTOR and NF-κB signaling pathways, as shown by KD/OE experiments in vitro and in vivo. |
MTT assay, western blot for PI3K/AKT/mTOR and NF-κB pathway components, KD/OE in breast cancer cells, in vivo xenograft |
Oncology letters |
Medium |
31885716
|
| 2021 |
miR-143 directly targets NRSN2 (binding relationship verified by dual luciferase assay); BMSC-derived extracellular vesicles deliver lncRNA MALAT1 into osteosarcoma cells where MALAT1 sponges miR-143, thereby de-repressing NRSN2 expression and activating Wnt/β-catenin signaling to promote osteosarcoma proliferation, invasion, and migration. |
Dual luciferase reporter assay, EV isolation and characterization, transfection of si-MALAT1 and miR-143 mimic, western blot for Wnt/β-catenin pathway proteins, in vivo xenograft |
OncoTargets and therapy |
Medium |
33564242
|
| 2021 |
miR-1913 directly targets NRSN2 (validated by dual luciferase reporter assay); hBMSC-derived exosomes deliver miR-1913 into osteosarcoma cells, suppressing NRSN2 expression and thereby inhibiting osteosarcoma cell viability, proliferation, migration, and invasion. |
Dual luciferase reporter assay, CCK8, colony formation, wound healing, transwell assays, RT-qPCR and western blot for NRSN2 and EMT markers, TEM and NTA for exosome characterization |
American journal of translational research |
Medium |
34650689
|
| 2022 |
NRSN2 activates the ERK1/2-Bcl-xL signaling pathway; miR-206 (delivered via BMSC-derived extracellular vesicles) directly targets NRSN2 (validated by dual luciferase assay), suppressing NRSN2-mediated ERK1/2-Bcl-xL activation and inhibiting osteosarcoma progression. |
Dual luciferase reporter assay, western blot for p-ERK1/2, ERK1/2, Bcl-xL, EdU and colony formation assays, flow cytometry for apoptosis, immunofluorescence, in vivo xenograft |
European journal of histochemistry |
Medium |
35730574
|
| 2022 |
E2F1 directly transcribes NRSN2 (confirmed by luciferase reporter and chromatin immunoprecipitation assays); the E2F1/NRSN2 axis promotes ESCC cell proliferation, migration, and invasion by activating the AKT/mTOR pathway. |
Luciferase reporter assay, chromatin immunoprecipitation (ChIP), loss- and gain-of-function assays, western blot for AKT/mTOR pathway, in vivo xenograft |
Pathology, research and practice |
Medium |
35662041
|
| 2024 |
NRSN2 promotes malignant behavior of HPV-transfected laryngeal carcinoma cells through activation of the AMPK/ULK1 pathway and consequent autophagy induction; NRSN2 knockdown suppresses AMPK/ULK1-mediated autophagy and restrains malignant behavior. |
RT-qPCR, immunoblotting, immunofluorescence, CCK-8, EdU staining, transwell, wound healing, flow cytometry, TEM for autophagosomes, AMPK/ULK1 pathway inhibition experiments |
Cancer biology & therapy |
Medium |
38569536
|
| 2024 |
NRSN2 knockout mice show significant alterations in functional brain network connectivity—particularly in sensory-related (gustatory and auditory) and default mode network regions—without marked changes in brain microstructure or regional activity, linking NRSN2 to sensory processing and stress resilience circuitry. |
11.7 T multimodal MRI (structural and functional) in Nrsn2 homozygous knockout mice compared with wild-type at juvenile and adult stages |
Phenomics |
Medium |
39723223
|
| 2024 |
lncRNA LUESCC functions as a ceRNA by sponging miR-6785-5p to enhance NRSN2 expression, which is critical for ESCC proliferation, migration, and invasion; this axis was mechanistically established by luciferase reporter assays and rescue experiments. |
Luciferase reporter assay (LUESCC/miR-6785-5p and miR-6785-5p/NRSN2 interactions), KD of LUESCC, rescue by NRSN2 modulation, in vitro and in vivo functional assays |
Cellular and molecular life sciences |
Medium |
38457049
|